Raymond James Financial
AQST icon

Raymond James Financial’s Aquestive Therapeutics AQST Stock Holding History

Raymond James Financial’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$229K Buy
55,222
+30,175
+120% +$122K ﹤0.01% 4818
2025
Q4 		$162K Buy
25,047
+8,472
+51% +$52.8K ﹤0.01% 4835
2025
Q3 		$92.7K Sell
16,575
-1,457
-8% -$6.3K ﹤0.01% 4758
2025
Q2 		$59.7K Buy
18,032
+1,000
+6% +$2.87K ﹤0.01% 5113
2025
Q1 		$49.4K Sell
17,032
-122,559
-88% -$371K ﹤0.01% 4642
2024
Q4 		$498K Buy
+139,591
New +$644K ﹤0.01% 3905

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Raymond James Financial's AQST Position: Q1 2026 in Review

Raymond James Financial increased its Aquestive Therapeutics (AQST) stake by 120% in Q1 2026, buying an estimated $122K and bringing the position to 55,222 shares worth $229K. The position accounts for ﹤0.01% of the portfolio, ranked #4818.

Raymond James Financial first reported a position in AQST in Q4 2024 and has held it in 6 quarters since. The position peaked at $498K in Q4 2024. 180 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • Raymond James Financial held 55,222 shares of Aquestive Therapeutics worth $229K as of Q1 2026.
  • Raymond James Financial bought 30,175 Aquestive Therapeutics shares in Q1 2026, an estimated $122K.
  • Aquestive Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #4818 holding.
  • Raymond James Financial first reported a position in Aquestive Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Raymond James Financial's Aquestive Therapeutics position peaked at $498K in Q4 2024.
  • 180 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.